These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 11385167)

  • 1. Percutaneous intervention in saphenous venous grafts: in-stent restenosis lesions are safer than de novo lesions.
    Assali AR; Sdringola S; Moustapha A; Ghani M; Achour H; Hale S; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR
    J Invasive Cardiol; 2001 Jun; 13(6):446-50. PubMed ID: 11385167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor long-term patient and graft survival after primary percutaneous coronary intervention for acute myocardial infarction due to saphenous vein graft occlusion.
    Brodie BR; VerSteeg DS; Brodie MM; Hansen C; Richter SJ; Stuckey TD; Gupta N; Pulsipher M; Downey W
    Catheter Cardiovasc Interv; 2005 Aug; 65(4):504-9. PubMed ID: 15988742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous saphenous vein graft interventions with and without distal filter wire protection.
    Hofmann M; Störger H; Schwarz F; Schwarz CE; Reinemer H; Ruef J; Schöpf J; Haase J
    J Interv Cardiol; 2005 Dec; 18(6):475-9. PubMed ID: 16336428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of the Symbiot PTFE-covered stent to reduce distal embolization during percutaneous coronary intervention in saphenous vein grafts.
    Blackman DJ; Choudhury RP; Banning AP; Channon KM
    J Invasive Cardiol; 2005 Nov; 17(11):609-12. PubMed ID: 16264208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous intervention on the saphenous vein bypass grafts--long-term outcomes.
    Bansal D; Muppidi R; Singla S; Sukhija R; Zarich S; Mehta JL; Sachdeva R
    Catheter Cardiovasc Interv; 2008 Jan; 71(1):58-61. PubMed ID: 18098183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era.
    Pucelikova T; Mehran R; Kirtane AJ; Kim YH; Fahy M; Weisz G; Lansky AJ; Moussa I; Gray WA; Collins MB; Kodali SK; Stone GW; Moses JW; Leon MB; Dangas G
    Am J Cardiol; 2008 Jan; 101(1):63-8. PubMed ID: 18157967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic total occlusion treatment in post-CABG patients: saphenous vein graft versus native vessel recanalization-long-term follow-up in the drug-eluting stent era.
    Meliga E; García-García HM; Kukreja N; Daemen J; Tanimoto S; Ramcharitar S; van Mieghem CA; Sianos G; van der Ent M; van der Giessen WJ; de Feyter P; van Domburg R; Serruys PW
    Catheter Cardiovasc Interv; 2007 Jul; 70(1):21-5. PubMed ID: 17584913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percutaneous coronary intervention of or through saphenous vein grafts or internal mammary arteries: the impact of stents, adjunctive pharmacology, and multicomponent distal protection.
    Morrison DA; Thai H; Goldman S; Felix E; Hernandez J
    Catheter Cardiovasc Interv; 2006 Apr; 67(4):571-9. PubMed ID: 16547927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arterial versus venous bypass grafts in patients with in-stent restenosis.
    Gaudino M; Cellini C; Pragliola C; Trani C; Burzotta F; Schiavoni G; Nasso G; Possati G
    Circulation; 2005 Aug; 112(9 Suppl):I265-9. PubMed ID: 16159829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Strategy for post coronary artery bypass grafting in patients with bypass graft stenosis: comparison of percutaneous transluminal coronary angioplasty for the native coronary artery, internal mammary artery and saphenous vein graft].
    Kawaguchi R; Hoshizaki H; Oshima S; Ito S; Hiratsuji T; Tsurugaya H; Ito I; Sekiguchi M; Takama N; Seta Y; Adachi H; Toyama T; Naito S; Kaneko T; Taniguchi K
    J Cardiol; 2001 Nov; 38(5):239-44. PubMed ID: 11729723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of drug-eluting stents in venous coronary artery bypass grafts.
    Hernandez-Antolín R; Alfonso F; Jimenez P
    EuroIntervention; 2009 May; 5 Suppl D():D51-7. PubMed ID: 19736072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized evaluation of polytetrafluoroethylene-covered stent in saphenous vein grafts: the Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts (RECOVERS) Trial.
    Stankovic G; Colombo A; Presbitero P; van den Branden F; Inglese L; Cernigliaro C; Niccoli L; Bartorelli AL; Rubartelli P; Reifart N; Heyndrickx GR; Saunamäki K; Morice MC; Sgura FA; Di Mario C;
    Circulation; 2003 Jul; 108(1):37-42. PubMed ID: 12821546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial clinical experience with distal protection using the FilterWire in patients undergoing coronary artery and saphenous vein graft percutaneous intervention.
    Popma JJ; Cox N; Hauptmann KE; Reifart N; Virmani R; Emira K; Murphy S; Gibson CM; Grube E
    Catheter Cardiovasc Interv; 2002 Oct; 57(2):125-34. PubMed ID: 12357506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft.
    Mehta RH; Honeycutt E; Peterson ED; Granger CB; Halabi AR; Shaw LK; Smith PK; Califf RM; Harrington RA; Sketch MH
    Circulation; 2006 Jul; 114(1 Suppl):I396-401. PubMed ID: 16820607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of distal embolic protection in saphenous vein graft interventions (an analysis of 19,546 patients in the American College of Cardiology-National Cardiovascular Data Registry).
    Mehta SK; Frutkin AD; Milford-Beland S; Klein LW; Shaw RE; Weintraub WS; Krone RJ; Anderson HV; Kutcher MA; Marso SP;
    Am J Cardiol; 2007 Oct; 100(7):1114-8. PubMed ID: 17884373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing dosimetry with high-dose intracoronary gamma radiation (21 Gy) for patients with diffuse in-stent restenosis.
    Kuchulakanti P; Torguson R; Canos D; Satler LF; Suddath W; Chan R; White LR; Gevorkian N; Bui A; Wang B; Kent KM; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2005; 6(3):108-12. PubMed ID: 16275606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts.
    Gioia G; Benassi A; Mohendra R; Chowdhury K; Masood I; Matthai W
    Catheter Cardiovasc Interv; 2008 Jul; 72(1):13-20. PubMed ID: 18561143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study.
    Ellis SG; Kandzari D; Kereiakes DJ; Pichard A; Huber K; Resnic F; Yakubov S; Callahan K; Borgman M; Cohen SA
    J Invasive Cardiol; 2007 Oct; 19(10):404-9. PubMed ID: 17906340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
    Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G
    J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal in-stent restenosis and in-stent thrombosis within the same bare-metal stent 5 years after deployment in a saphenous vein graft.
    Ponnuthurai FA; van Gaal WJ; Channon KM
    J Invasive Cardiol; 2007 Dec; 19(12):E369-71. PubMed ID: 18180530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.